全文获取类型
收费全文 | 4438篇 |
免费 | 299篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 102篇 |
妇产科学 | 64篇 |
基础医学 | 534篇 |
口腔科学 | 57篇 |
临床医学 | 490篇 |
内科学 | 972篇 |
皮肤病学 | 32篇 |
神经病学 | 295篇 |
特种医学 | 165篇 |
外科学 | 833篇 |
综合类 | 49篇 |
一般理论 | 3篇 |
预防医学 | 343篇 |
眼科学 | 94篇 |
药学 | 322篇 |
中国医学 | 1篇 |
肿瘤学 | 361篇 |
出版年
2024年 | 8篇 |
2023年 | 52篇 |
2022年 | 80篇 |
2021年 | 190篇 |
2020年 | 77篇 |
2019年 | 159篇 |
2018年 | 157篇 |
2017年 | 105篇 |
2016年 | 113篇 |
2015年 | 131篇 |
2014年 | 218篇 |
2013年 | 243篇 |
2012年 | 384篇 |
2011年 | 392篇 |
2010年 | 232篇 |
2009年 | 173篇 |
2008年 | 280篇 |
2007年 | 302篇 |
2006年 | 251篇 |
2005年 | 265篇 |
2004年 | 216篇 |
2003年 | 226篇 |
2002年 | 190篇 |
2001年 | 38篇 |
2000年 | 42篇 |
1999年 | 26篇 |
1998年 | 33篇 |
1997年 | 20篇 |
1996年 | 19篇 |
1995年 | 7篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1978年 | 3篇 |
1976年 | 3篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1967年 | 2篇 |
1908年 | 8篇 |
1907年 | 3篇 |
1870年 | 1篇 |
排序方式: 共有4747条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
6.
Peter D. Le Roux David S. Jardine Paul M. Kanev John D. Loeser 《Child's nervous system》1991,7(1):34-39
We reviewed the results of all pediatric patients undergoing intracranial pressure (ICP) monitoring in a 2-year period at our institution. The outcome of patients suffering hypoxia or ischemic injuries (HII) is compared to those suffering non-hypoxic or non-ischemic injuries (NHII). Thirty-four patients had ICP monitors placed during the study period. Inconplete patient information led to the exclusion of 5 patients. An additional 5 patients were excluded because no measures to control ICP were taken after the monitor was placed. Twenty-four patients required treatment for raised ICP (hyperventilation, 24; mannitol, 19; barbiturate coma, 6). Admission Glasgow Coma Score in patients suffering HII (median score 5) and NHII (median score 6) were not significantly different (Mann-Whitney U Test). Only 2 of 8 patients with HII were near-drowning vietims. The remaining 6 had HII from other causes (5 survivors of various forms of asphyxia and 1 of cardiac arrest). All 8 patients had poor outcomes (1 severely disabled; 7 died). The 16 patients with NHII had a variety of diagnoses (6 trauma, 5 encephalitis, 4 bacterial meningitis, 1 diabetic ketoacidosis). Among these, 6 had good outcomes and 10 poor outcomes (2 severely disabled, 2 vegetative, and 6 died). The difference in outcome between patients with NHII and HII is significant at P=0.059 (Fischer Exact test). Patients with NHII may benefit from ICP monitoring. Patients with HII from near-drowning and other causes did not appear to benefit from ICP monitoring and interventions directed at controlling ICP. 相似文献
7.
8.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
9.
Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due to Bordetella pertussis in a Murine Model 下载免费PDF全文
Darren P. Ennis Joseph P. Cassidy Bernard P. Mahon 《Clinical and Vaccine Immunology : CVI》2005,12(3):409-417
The prevalence of asthma and allergic disease has increased in many countries, and there has been speculation that immunization promotes allergic sensitization. Bordetella pertussis infection exacerbates allergic asthmatic responses. We investigated whether acellular pertussis vaccine (Pa) enhanced or prevented B. pertussis-induced exacerbation of allergic asthma. Groups of mice were immunized with Pa, infected with B. pertussis, and/or sensitized to ovalbumin. Immunological, pathological, and physiological changes were measured to assess the impact of immunization on immune deviation and airway function. We demonstrate that immunization did not enhance ovalbumin-specific serum immunoglobulin E production. Histopathological examination revealed that immunization reduced the severity of airway pathology associated with sensitization in the context of infection and decreased bronchial hyperreactivity upon methacholine exposure of infected and sensitized mice. These data demonstrate unequivocally the benefit of Pa immunization to health and justify selection of Pa in mass vaccination protocols. In the absence of infection, the Pa used in this study enhanced the interleukin-10 (IL-10) and IL-13 responses and influenced airway hyperresponsiveness to sensitizing antigen; however, these data do not suggest that Pa contributes to childhood asthma overall. On the contrary, wild-type virulent B. pertussis is still circulating in most countries, and our data suggest that the major influence of Pa is to protect against the powerful exacerbation of asthma-like pathology induced by B. pertussis. 相似文献
10.
Denise M Connor Shawn Binkley Neil O Fishman Leanne B Gasink Darren Linkin Ebbing Lautenbach 《Infection control and hospital epidemiology》2007,28(12):1408-1410
We examined the possible unintended consequences of a 72-hour automatic order to discontinue vancomycin therapy in an antimicrobial stewardship program (ASP). Of 120 patients, 11 had vancomycin therapy discontinued at 72 hours without a call to the ASP, and 7 experienced a treatment interruption of 6-36 hours. All discontinuation of therapy was considered appropriate, and the 7 treatment interruptions did not have clear clinical consequences. Only one-third of patients had ASP stickers that warned of impending discontinuation of vancomycin therapy placed appropriately in the medical record. 相似文献